OmniAb Investor Presentation Deck

Approved and Clinical-Stage Partner Pipeline as of 03/31/2023 THREE APPROVED PRODUCTS AND 24 ACTIVE CLINICAL-STAGE ANTIBODIES Target Source Animal OmniRat OmniRat Therapy Area Oncology Oncology OmniRat Oncology OmniRat Immunology OmniRat Oncology Oncology OmniRat OmniRat OmniMouse Oncology Oncology Oncology OmniRat OmniRat Oncology OmniRat Oncology OmniRat Oncology OmniRat Oncology OmniRat Oncology OmniRat Oncology OmniFlic Oncology OmniFlic Oncology OmniFlic Oncology OmniRat Metabolic OmniRat OmniRat OmniChicken Partner Program gloria ARCUS GILEAD Zimberelimab BIOSCIENCE 1381 HANALL'>< 基石药业 CSTONE Janssen Jehon HARBOUR IMMUNOVANT BIONED Genentech A Member of the Roche Group Genmab BIONTECH Merck Aptevo Janssen Pfizer Janssen tehen *...* Genmab OCTTQ symphogen a Servier Company symphogen a Servier Company symphogen a Serviar Company abbvie AstraZeneca AMGEN SalubrisBio CURON Zhilkang Hongyi Boehringer Undisclosed Merck Genmab BIONTECH Janssen Sugemalimab Teclistamab Batoclimab Tiragolumab GEN1046 M6223 APVO436 JNJ-70218902 JNJ-78306358 GEN1047 S095017 S095018 S095024 S095029 ABBV-383 TNB-486 AMG 340 SAL003 CN1 Undisclosed Undisclosed Undisclosed M9140 GEN1053 JNJ-79635322 SGEN-BB228 OmniRat OmniRat OmniRat OmniRat OmniRat PD-1 PD-L1 BCMA x CD3 FcRn TIGIT PD-L1 x 4-1BB TIGIT CD123 x CD3 Undisclosed HLA-G x CD3 B7H4 x CD3 LAG-3 TIM-3 CD73 NKG2A BCMA x CD3 CD19 x CD3 PSMA x CD3 PCSK9 Undisclosed Undisclosed Undisclosed Gastrointestinal Undisclosed CEACAM-5 CD27 Oncology Oncology Undisclosed Oncology Oncology Oncology Oncology Phase 1 Phase 2 Phase 3 Registration Approved Undisclosed Seagen CD228 x 4-1BB Animal launch year: OmniRat 2012; OmniMouse 2014; OmniFlic 2014; OmniChicken 2016; OmniClic 2019; OmniTaur 2020 Notes: Most advanced status for each program shown. Zimberelimab and Sugemalimab are approved and marketed in China. Teclistamab is approved and marketed in the US and EU with $35M launch milestones paid. Indicates program with fully paid license from OMT, Inc. prior to acquisition. Programs discovered by Teneobio under a fully paid license. Future programs discovered under license agreement are subject to downstream economics. 39 OmniAb

View entire presentation